UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Transfusion medicine and hemotherapy, 2017-09, Vol.44 (5), p.327-336

2017

Volltextzugriff (PDF)

Editorial: Effector functions of therapeutic antibodies

Frontiers in immunology, 2023-01, Vol.13, p.1126966-1126966

2023

Volltextzugriff (PDF)

Tribody [(HER2) 2 xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Frontiers in immunology, 2018-04, Vol.9, p.814-814

2018

Volltextzugriff (PDF)

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth

Haematologica (Roma), 2021-09, Vol.106 (9), p.2507

2021

Volltextzugriff (PDF)

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

The Journal of immunology (1950), 2011-02, Vol.186 (3), p.1840-1848

2011

Volltextzugriff (PDF)

Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy

Signal transduction and targeted therapy, 2024-07, Vol.9 (1), p.172-3, Article 172

2024

Volltextzugriff (PDF)

Targeted siRNA nanocarrier: a platform technology for cancer treatment

Oncogene, 2022-04, Vol.41 (15), p.2210-2224

2022

Volltextzugriff (PDF)

Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3

Frontiers in immunology, 2024-01, Vol.14, p.1286097-1286097

2024

Volltextzugriff (PDF)

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils

Frontiers in immunology, 2019-01, Vol.9, p.3124-3124

2019

Volltextzugriff (PDF)

Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength

Frontiers in immunology, 2021-01, Vol.11, p.609941-609941

2021

Volltextzugriff (PDF)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Haematologica (Roma), 2021-07, Vol.106 (7), p.1857-1866

2021

Volltextzugriff (PDF)

Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity

Frontiers in immunology, 2020-06, Vol.11, p.1328-1328

2020

Volltextzugriff (PDF)

Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies

Viruses, 2024-04, Vol.16 (4), p.596

2024

Volltextzugriff (PDF)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Frontiers in immunology, 2022-10, Vol.13, p.929339-929339

2022

Volltextzugriff (PDF)

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

Cancer science, 2021-08, Vol.112 (8), p.3029-3040

2021

Volltextzugriff (PDF)

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

Haematologica (Roma), 2017-02, Vol.102 (2), p.381-390

2017

Volltextzugriff (PDF)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Frontiers in immunology, 2022-08, Vol.13, p.949140-949140

2022

Volltextzugriff (PDF)

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

Frontiers in immunology, 2023-10, Vol.14, p.1227572-1227572

2023

Volltextzugriff (PDF)

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Geburtshilfe und Frauenheilkunde, 2021-06, Vol.81 (6), p.666-678

2021

Volltextzugriff (PDF)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

mAbs, 2024, Vol.16 (1), p.2315640-2315640

2024

Volltextzugriff (PDF)

The relevance of complement in pemphigoid diseases: A critical appraisal

Frontiers in immunology, 2022-08, Vol.13, p.973702-973702

2022

Volltextzugriff (PDF)

Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition

mAbs, 2023, Vol.15 (1), p.2236265-2236265

2023

Volltextzugriff (PDF)

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells

Frontiers in immunology, 2019, Vol.10, p.2044-2044

2019

Volltextzugriff (PDF)

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

The Journal of immunology (1950), 2010-01, Vol.184 (1), p.512-520

2010

Volltextzugriff (PDF)

Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo

Frontiers in immunology, 2020-01, Vol.10, p.3024-3024

2020

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(108)
Humans
(83)
Immunology
(50)
Animals
(48)
Cell Line, Tumor
(38)
Mice
(31)
Immunotherapy
(30)
Hematology
(27)
Oncology
(26)
Antibodies
(20)
Adcc
(18)
Biological And Medical Sciences
(18)
Cytotoxicity
(18)
Female
(18)
Tumors
(15)
Medical Sciences
(14)
Antibody-Dependent Cell Cytotoxicity
(13)
Antibody-Dependent Cell Cytotoxicity - Immunology
(13)
Cancer
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Editorial: Effector functions of therapeutic antibodies

Tribody [(HER2) 2 xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy

Targeted siRNA nanocarrier: a platform technology for cancer treatment

Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils

Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity

Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

The relevance of complement in pemphigoid diseases: A critical appraisal

Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo

Suchergebnisse filtern